Independent Innovators : Honoring this year’s standouts for their imagination, resourcefulness, and perseverance Influenza treatment update Pharmaceutical waste and public health HPV immunization and reimbursement
FDA Approves Lebrikizumab-lbkz for Moderate-to-Severe Atopic Dermatitis
September 16th 2024Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.